[A23-138] Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2024
Project no.:
A23-138
Commission:
Commission awarded on 15.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
First-line treatment of advanced or unresectable hepatocellular carcinoma in adult patients
Result of dossier assessment:
- Patients with Child-Pugh A or no hepatic cirrhosis: added benefit not proven
- Patients with Child-Pugh B: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A23-138_en
| Project no. | Title | Status |
|---|---|---|
| A23-27 | Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-30 | Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-29 | Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-31 | Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-26 | Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-87 | Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-69 | Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |